Ciprofloxacin

Generic Name: Ciprofloxacin

Brand Names: Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈FN_₃O_₃

CAS Number: 85721-33-1

Unique Ingredient Identifier: 5E8K9I0O4U

Background: Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.

The first ciprofloxacin containing product was FDA approved on 22 October 1987.

Indication: Ciprofloxacin is only indicated in infections caused by susceptible bacteria.

Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.

A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa. Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa. A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.

A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis. A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.

A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.

Associated Conditions: Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae

Clinical Trials

CAT BITE Antibiotic Prophylaxis for the Hand/Forearm (CATBITE)

Phase 4

Recruiting

Conditions: Cat Bite
Anti-bacterial Agents
Hand Injuries
Arm Injury
Infection, Bacterial

Interventions: Drug: Amoxicillin/clavulanate
Other: Placebo (microcrystalline cellulose)
Procedure: Wound management
Drug: Ciprofloxacin
Drug: Clindamycin

First Posted Date: 2023-05-06

Last Posted Date: 2024-10-01

Lead Sponsor: University of Missouri-Columbia

Target Recruit Count: 72

Registration Number: NCT05846399

Locations: 🇺🇸
University of Missouri, Columbia, Missouri, United States

A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Vorasidenib 40 mg Oral Tablet
Drug: Vorasidenib 10 mg Oral Tablet
Drug: Ciprofloxacin 500 mg Oral Tablet

First Posted Date: 2023-05-06

Last Posted Date: 2025-02-14

Lead Sponsor: Servier Bio-Innovation LLC

Target Recruit Count: 64

Registration Number: NCT05843708

Locations: 🇺🇸
PPD Development, Austin, Texas, United States

LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media

Not Applicable

Completed

Conditions: Upper Respiratory Tract Infections

Interventions: Drug: 0.9% NaCl physiological saline Nasal-spraying
Combination Product: LiveSpo Navax®
Drug: Augmentin 500Mg Tablet
Drug: Xylometazoline Nasal
Drug: Acetylcysteine
Drug: Cefotaxime
Drug: Ciprofloxacin

First Posted Date: 2023-04-07

Last Posted Date: 2024-08-22

Lead Sponsor: Anabio R&D

Target Recruit Count: 175

Registration Number: NCT05804123

Locations: 🇻🇳
Thai Binh University of Medicine and Pharmacy, Thai Binh Medical University Hospital and Thai Binh Children's Hospital, Thai Binh, Vietnam

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension

Phase 2

Recruiting

Conditions: Haematological Malignancy
Hypogammaglobulinemia

Interventions: Drug: trimethoprim-sulfamethoxazole (co-trimoxazole)
Drug: amoxycillin/clavulanic acid and ciprofloxacin
Drug: Immunoglobulins

First Posted Date: 2023-01-10

Last Posted Date: 2024-04-19

Lead Sponsor: Monash University

Target Recruit Count: 300

Registration Number: NCT05678621

Locations: 🇦🇺
Canberra Hospital, Garran, Australian Capital Territory, Australia
🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia
🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia

and more 4 locations

Bioequivalence Study of Ciprofloxacin in Healthy Adult Subjects Under Fasting Condition

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Ciproxin 750 mg
Drug: Ciprofloxacin 750 mg

First Posted Date: 2022-09-08

Last Posted Date: 2022-09-08

Lead Sponsor: Future University in Egypt

Target Recruit Count: 30

Registration Number: NCT05532267

Locations: 🇪🇬
Future Research Center (FRC), Cairo, New Cairo, Egypt

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Cancer

Interventions: Procedure: Biopsy
Drug: FOLFIRINOX
Drug: Ciprofloxacin
Drug: Metronidazole
Drug: Pembrolizumab
Procedure: Surgical Resection

First Posted Date: 2022-07-18

Last Posted Date: 2024-10-15

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 25

Registration Number: NCT05462496

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Modified Surface of PLGA Nanoparticles in Smart Hydrogel

Early Phase 1

Completed

Conditions: Antibiotic Resistant Infection

Interventions: Drug: Ciprofloxacin

First Posted Date: 2022-07-05

Last Posted Date: 2022-07-05

Lead Sponsor: British University In Egypt

Target Recruit Count: 55

Registration Number: NCT05442736

Locations: 🇪🇬
Mona Arafa, Cairo, Egypt

A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Ciprofloxacin 750 MG
Drug: PrimeC 748 mg
Drug: Celecoxib 200mg

First Posted Date: 2022-06-29

Last Posted Date: 2023-02-08

Lead Sponsor: NeuroSense Therapeutics Ltd.

Target Recruit Count: 19

Registration Number: NCT05436678

Locations: 🇺🇸
Novum, Las Vegas, Nevada, United States

Efficacy Of Doxycycline & Versus Rifampin In Treatment Of Rhinoscleroma

Phase 1

Conditions: Rhinoscleroma

Interventions: Drug: Doxycycline
Drug: Rifampin
Drug: Ciprofloxacin

First Posted Date: 2022-06-24

Last Posted Date: 2022-07-07

Lead Sponsor: Assiut University

Target Recruit Count: 45

Registration Number: NCT05431673

Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis

Phase 4

Recruiting

Conditions: Endocarditis Infective

First Posted Date: 2022-06-01

Last Posted Date: 2025-03-11

Lead Sponsor: Fundacion Clinic per a la Recerca Biomédica

Target Recruit Count: 360

Registration Number: NCT05398679

Locations: 🇪🇸
Hospital Virgen de la Macarena, Sevilla, Andalucía, Spain
🇪🇸
Hospital Virgen del Rocío, Sevilla, Andalucía, Spain
🇪🇸
Parc Taulí Hospital Universitari, Sabadell, Barcelona, Spain

and more 17 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy